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Abstract
Background: Levels of non-neutralising antibodies (AB) to the C5 domain of HIV Env gp120 are inversely related
to progression of HIV infection. In this phase I/II clinical study we investigated safety of Vacc-C5, a peptide-based
therapeutic vaccine candidate corresponding to C5/gp41732–744 as well as the effects on pre-existing AB levels to
C5/gp41732–744, immune activation and T cell responses including exploratory assessments of Vacc-C5-induced T
cell regulation. Our hypothesis was that exposure of the C5 peptide motif may have detrimental effects due to
several of its HLA-like features and that enhancement of non-neutralising anti-C5 AB by vaccination could reduce
C5 exposure and thereby chronic immune activation.
Methods: Thirty-six HIV patients on effective antiretroviral therapy were randomised to one of three dose levels of
Vacc-C5 administered intramuscularly with Alhydrogel or intradermally with GM-CSF as adjuvant through initial
immunisation and two booster periods over 26 weeks. Vacc-C5-specific AB were measured by ELISA and T cell
responses by both IFN-γ ELISPOT and proliferative assays analysed by flow cytometry. Immune regulation was
assessed by functional blockade of the two inhibitory cytokines IL-10 and TGF-β in parallel cultures. Non-parametric
statistical tests were applied.
Results: Vacc-C5 was found safe and well tolerated in all patients. Only marginal changes in humoral and cellular
responses were induced, without any effect on immune activation. Overall, anti-Vacc-C5 AB levels seemed to decrease
compared to pre-existing levels. Whereas Vacc-C5-specific CD8+ T cell proliferative responses increased after the first
booster period (p = 0.020; CD4+, p = 0.057), they were reduced after the second. In contrast, Vacc-C5-induced T cell
regulation increased after completed vaccination (p ≤ 0.027) and was lower at baseline in the few AB responders
identified (p = 0.027).
Conclusions: The therapeutic HIV vaccine candidate Vacc-C5 safely induced only marginal immune responses,
whereas Vacc-C5-induced T cell regulation markedly increased. Our data support further attention on immune
regulation during therapeutic HIV vaccination studies.
Trial registration: NCT01627678.
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Background
More than 30 years after its discovery, Human Immuno-
deficiency Virus type 1 (HIV) remains a global challenge
with more than 36 million people infected worldwide
[1]. Despite the achievements of effective antiretroviral
therapy (ART), patients with access to ART control
viremia but are not cured. Chronic immune activation is
reduced, but persists [2] and is associated with non-AIDS
morbidity and mortality [3, 4], an increasing concern in
the long term care of HIV patients. Search for alternative
treatment strategies are therefore warranted.
Vacc-C5 is a peptide-based therapeutic vaccine candi-
date that aims to induce non-neutralising antibodies
(AB) to the 5th constant domain (C5) of the HIV-1 en-
velope glycoprotein gp120 in conjunction with part of
the transmembrane glycoprotein of gp41. The presence
of AB towards the C5 region has previously been shown
to correlate with a slower disease progression [5–7].
Analysis of serum from treatment naïve patients has
demonstrated higher levels of non-neutralising anti-
Vacc-C5 AB levels in HIV natural viral suppressors
with moderate viral loads (<10,000 copies/ml) than in
patients with higher viral loads (>10,000 copies/ml).
Furthermore, longitudinal analysis of HIV patients has
revealed an inverse correlation between anti-Vacc-C5
AB levels and disease progression [8]. The C5 domain
has sequence similarity to peptide binding sites on
HLA molecules [9] and can bind both defined class II
and class I restricted peptides, bindings that are
blocked with anti-C5 monoclonal AB [10]. It has there-
fore been proposed that exposed C5 could amplify
chronic immune activation, either directly by cross-
signalling via HLA-like motifs or by presentation of
peptides that facilitate alloactivation-like responses
[11]. Our hypothesis was that any detrimental effects of
C5 explain the inverse relationship between anti-C5 AB
levels and clinical progression, and that enhancement
of non-neutralising anti-C5 AB by vaccination with
Vacc-C5 could reduce exposure of C5.
Against this background, a phase I/II trial was con-
ducted with the primary objective to evaluate safety of
Vacc-C5 at three dose levels administered either intra-
dermally or intramuscularly with two different adjuvants
while on effective ART. Local low dose granulocyte-
macrophage colony-stimulating factor (GM-CSF) facili-
tates dermal dendritic cell maturation and migration to
the lymph nodes for antigen presentation [12, 13] and
has been used in former studies with intradermal admin-
istration of the peptide-based HIV Gag p24 vaccine
Vacc-4× [14, 15] and with peptide-based cancer vaccines
[16]. Alhydrogel, the only adjuvant approved and mar-
keted for worldwide use (e.g. pneumococcal vaccine
Prevnar and HPV vaccine Gardasil), was applied in the
intramuscularly administered vaccine.
The secondary objectives were to explore humoral re-
sponses to Vacc-C5, HIV-associated immune activation
and T cell immunogenicity. T cell responses to HIV anti-
gens, such as C5, may be strongly regulated in chronic
HIV infection [17–19], and immune regulatory mecha-
nisms to HIV vaccine antigens may therefore be important
to consider before and during therapeutic HIV vaccination
[20, 21]. We have previously assessed an exploratory par-
ameter for vaccine antigen-induced T cell regulation,
based on simultaneous blockade of the two potent, soluble
cytokines downregulating HIV-specific T cell proliferation,
a key feature of effector T cells [22, 23]. Our approach
does not intend to differentiate the mechanistic pathways
of immune regulation, but rather measure the net impact
on proliferative capacity of effector T cells to simplify im-
plementation in a clinical trial setting.
This parameter of immune regulation was addressed
also in the present study, and whereas only marginal
cellular and humoral immune responses were induced,
vaccine-specific regulation markedly increased after
completed vaccination. These results may illustrate the
complexity of therapeutic HIV vaccination in general
and may also hopefully encourage further attention on
assessments of immune regulation.
Methods
Study design and immunisation schedule
Thirty-six HIV-infected patients (male n = 35; female
n = 1) from the Outpatient Clinic, Department of Infec-
tious Diseases, Oslo University Hospital were enrolled in
this open, dose escalating phase I/II trial (Fig. 1). Patients
between 18 and 55 years of age, infected for at least one
year, on effective ART for the last six months with viral
load <50 copies/ml, CD4+ T cell count >400/μl and nadir
CD4+ count >200/μl were included. Exclusion criteria
were AIDS-defining illnesses, malignancies, chronic active
infections, immunosuppressive therapy or unacceptable
general biochemical and hematological parameters. Preg-
nant or breastfeeding women were excluded.
The participants were openly and sequentially rando-
mised to three dose groups with 12 patients in each
group, and included to the allocated dose within three
months after screening.
Within each dose group, patients were randomised to
either intradermal injections (n = 6) of Vacc-C5 given
10 min after administration of the local adjuvant GM-
CSF, or intramuscular injections (n = 6) of Vacc-C5
with Alhydrogel as adjuvant.
During the study period of 26 weeks, the participants
received a total of seven doses of Vacc-C5 at either low
(LD, 100 μg), medium (MD, 300 μg) or high dose (HD,
900 μg) administered at week 1, 2, 4 (primary immun-
isation), 12, 13 (first boost), 21 and 22 (second boost).
Dose Review Group Decision meetings were regularly
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held to evaluate safety before the higher dose level was
administered.
The study was approved by the Norwegian Regional
Ethics Committee South-East and the Norwegian Medi-
cines Agency (EudraCT 2012–000710-11) and regis-
tered at www.clinicaltrials.gov (NCT01627678). Written
informed consent was obtained from all participants.
The trial was carried out in accordance with the Inter-
national Conference on Harmonisation Guideline for
Good Clinical Practice.
Peptide design and adjuvants
Vacc-C5 (Bionor Pharma, Oslo, Norway), a single het-
erodimeric peptide corresponding to the C5 domain on
gp120501–512 and the external domain of gp41732–744,
was supplied as sterile vials of freeze-dried powder and
administered at doses of 100 μg, 300 μg or 900 μg
reconstituted in water.
In the intradermal group, 0.1 ml of GM-CSF (Leukine™)
(Bayer HealthCare pharmaceuticals LLC, Seattle, WA) at
0.60 mg/ml was given intradermally superficial to the left
deltoid muscle 10 min before 0.1 ml of Vacc-C5 at the
same site. In the intramuscular group, Alhydrogel (Apotek
production & Laboratorier AB, Umeå, Sweden) was added
to Vacc-C5 at a ratio of 1:1.5 in a total volume of 0.25 ml
and administered in the left triceps muscle.
The vaccine was prepared by the Oslo University Hos-
pital pharmacy on the day of administration.
Monitoring and blood sampling
Adverse events were monitored, and clinical examin-
ation performed at each visit. Blood samples for safety
(general biochemistry and hematology), CD4+ and CD8+
T cell counts and HIV RNA were analysed by approved
methods. Peripheral blood mononuclear cells (PBMC)
were obtained from CPT tubes (Becton Dickinson
Biosciences, San Jose, CA) (BD), processed and stored
at −150 °C until further analysis. Serum was processed
and stored at −70 °C on site before being sent to
Huntingdon Life Sciences (Huntingdon, Cambridgeshire,
England) to assess anti-Vacc-C5 AB levels. Blood sam-
ples drawn at a day of vaccination were collected prior
to immunisations.
Vacc-C5-specific antibodies in serum
ELISA plates (Fisher Scientific, UK) coated with Vacc-C5
(i.e. the C5 and gp41 regions combined) were added
200 μl blocking buffer (BSA in PBS) and incubated for
2 h. 100 μl standards (Aalto Bio Reagents Sheep anti-
HIV-1 gp120 AB, concentrations 0–5000 ng/mL), con-
trols and samples diluted 1:5 were added and plates
incubated for 2 h at 37 °C.
100 μl Protein G-alkaline Phosphatase Conjugate
(3 μg/ml) (Calbiochem, UK) were added and plates incu-
bated for 1 h before 100 μl Alkaline Phosphatase Yellow
Substrate (Sigma-Aldrich, UK) (S-A) were added and
plates incubated for 15 min. A stop solution containing
Trizma Base (S-A), EDTA, NaOH and NaN3 was used.
Raw data were processed in Watson LIMS, using a
5PL (auto-estimate) algorithm with a weighting factor of
1/Y. Limit of detection was 390.7 ng/ml, and levels
below were set to 390 ng/ml. A responder was defined
as a patient with an increased AB level from baseline to
end of study.
Fig. 1 The CONSORT diagram. Patients were randomised to low (LD, 100 μg), medium (MD, 300 μg) or high dose (HD, 900 μg) with GM-CSF or
Alhydrogel as adjuvant
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Vacc-C5-specific T cell responses by ELISPOT
The IFN-γ enzyme-linked immunosorbent spot (ELI-
SPOT) assay was performed on PBMC, collected at
week 1 (baseline), 6, 15 and 26 (end of study), as
instructed by the manufacturer (Mabtech, Nacka Strand,
Sweden). The plates were washed with sterile PBS, con-
ditioned with albumin-containing PBS and incubated at
room temperature for 30 min. Cryopreserved PBMC
were thawed and rested overnight before stimulated in
triplicate wells with pooled Vacc-C5 15-mer overlapping
peptides offset by 1 amino acid at 2 μg/ml/peptide;
200,000 PBMC/well in 200 μl medium (Gibco AIM V,
Invitrogen/Life technologies, San Diego, CA). Staphylo-
coccal enterotoxin B (SEB)-stimulated (S-A) and un-
stimulated cells were positive and negative controls,
respectively. The plates were incubated overnight at 37 °
C and 5% CO2 before they were washed and 7-B6–1-
ALP conjugate added. After 2 h of incubation at room
temperature the plates were washed and the substrate
solution added. Spots developed for 12 min before the
plates were washed extensively in tap water to stop the
process.
IFN-γ spot forming units (SFU) were counted by an
AID ELISPOT reader with AID ELISPOT v5 Scanner
software (AID GmbH, Strassberg, Germany). Net SFU
were determined by subtracting corresponding negative
controls for each sample. No cut-off for positive re-
sponse was defined. Median values of triplicates were
used for analysis, and data given as SFU per 106 input
cells. All four time-points for a given patient were run
on the same day to avoid inter-assay variation.
T cell proliferation and regulation
Fifteen patients were selected for T cell proliferation and
regulation assays at week 1, 6, 15 and 26. These included
the six patients with a specific T cell ELISPOT responder
profile at some time-point, defined by at least twice the
negative control, regardless of their AB responses. Add-
itionally, nine patients with varying AB responses were
selected. They had either an increase in Vacc-C5 AB
from baseline to end of study (n = 4), an increase in AB
at some time-point (n = 3) or no AB response at all
(n = 2). Every dose group (n = 6: 3: 6, LD: MD: HD, re-
spectively) and both adjuvants (GM-CSF n = 6; Alhydro-
gel n = 9) were represented.
Cryopreserved PBMC were thawed and rested over-
night before they were labelled with carboxyfluorescein
succinimidyl ester (CFSE) (Invitrogen Molecular Probes,
Eugene, OR) at 2 μM for 5 min and subsequently stimu-
lated with pooled overlapping Vacc-C5 15-mer peptide
panels at 2 μg/ml/peptide. SEB (S-A) at 0.5 μg/ml was
used as positive control. 250,000 PBMC were cultured in
200 μl serum-free culture medium (Gibco AIM V, Invi-
trogen/Life technologies, San Diego, CA) at 37 °C and
5% CO2 in 96-well tissue-culture plates (Nunc, Roskilde,
Denmark). At day 6, cells were harvested and stained
with CD3 V450, CD8 APC-H7 and to exclude nonviable
cells, 7-aminoactinomycin (7AAD) (BD). Vacc-C5-
specific proliferative T cell responses were defined as
percentages of live (7AAD−) CFSEdim CD8+ or CD4+ (i.e.
CD8−) CD3+ T cells. The cut-off for the proliferated
CFSEdim T cell subset was set by median fluorescence in-
tensities equal to or below the second proliferated gener-
ation. Net responses were found by subtracting
background proliferation in the corresponding unstimu-
lated control cultures. All four time-points for a given
patient were run on the same day.
Inhibitory monoclonal antibodies (mAbs) to soluble
interleukin-10 (IL-10) and transforming growth factor-β
(TGF-β) were added to parallel antigen and control cul-
tures at 10 μg/ml final concentration according to the
manufacturer’s instructions (anti-IL-10 clone 23,738,
anti-TGF-β clone 1D11; R&D Systems Europe, Abing-
don, UK). Antigen-induced cytokine-mediated net regu-
lation was defined as the difference in proliferative
responses between antigen cultures with and without
mAbs to IL-10 and TGF-β. Fold increase was the ratio
between Vacc-C5 proliferative responses with and with-
out blocking mABs.
T cell activation markers
Cryopreserved PBMC from all 36 patients collected at
week 1, 6, 15 and 26 were thawed and rested overnight
before they were stained with CD3 V450, CD8 APC-H7,
HLA-DR APC and CD38 PE (BD). Activation was given
as percentages of HLA-DR+CD38+ CD8+ or CD4+ (i.e.
CD8−) CD3+ T cells.
For both T cell proliferation and activation markers
flow cytometry data were obtained with BD FACS Canto
II™ with BD Diva software v6.1.
Analyses of soluble markers
The soluble pro-inflammatory chemokine interferon-
gamma inducible protein 10 (IP-10) and cytokine IL-6
were analysed in snap frozen serum from all 36 patients
at week 1, 6, 15 and 26 by Quantikine ELISA kits (R&D
Systems, Abingdon, England) according to the instruc-
tions by the manufacturer. IP-10 samples were diluted
1:5. All samples for each individual were run in dupli-
cates on the same plate.
Statistical methods
Statistical analyses were performed by Statistica v7 (Stat-
Soft, Tulsa, OK) using non-parametrical statistics.
Mann-Whitney U test or Kruskal-Wallis was applied to
compare two or more groups. Wilcoxon matched pairs
test was used for dependent variables, Spearman rank
for correlations and Fisher exact test to test proportional
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differences. All data are presented as medians (inter-
quartile ranges, IQR). p-values <0.05 were considered
significant. Graphics were done by GraphPad Prism v6
(GraphPad Software, La Jolla, CA).
Results
Safety and tolerability
All 36 patients completed the study. Their baseline
characteristics are presented in Table 1. For more de-
tails, see Table 2. Vacc-C5 was safe and well tolerated,
although many patients in the intradermal vaccination
group experienced transient (seconds) pain/discomfort
at the injection site during administration. No serious
adverse event related to study drug was reported, and
no significant changes in clinical status, vital signs, la-
boratory parameters, HIV RNA, CD4+ or CD8+ T cell
counts were observed.
Anti-Vacc-C5 antibodies
Anti-Vacc-C5 AB were detected in 24 patients (67%) at
baseline. AB levels were generally low (median 1433 ng/
ml), but comparable to previous assessments (with an-
other ELISA assay) in 102 cross-sectional sampled HIV
patients on ART (median 1160 ng/ml) where 80% of the
sera carried <10,000 ng/ml (data not shown). Despite ran-
domisation, AB levels were significantly higher in the HD
group compared to the LD group at baseline (Fig. 2b), but
vaccine induced changes were evaluated relative to the in-
dividual’s own baseline AB level in the following.
From baseline to end of study, AB levels slightly
decreased in the entire vaccinated group (p = 0.004)
(Fig. 2a). When data for both adjuvants were combined
in dose groups, AB levels were reduced in the MD
(p = 0.025) and possibly the HD group (p = 0.059)
whereas no changes were observed in the LD group
(p = 0.327) (Fig. 2b).
Changes in the anti-Vacc-C5 AB levels over time did
not differ between the intradermal and the intramuscu-
lar group (data not shown). However, when we divided
the cohort further into groups based on both dose and
administration, AB responses tended to decrease in the
intradermal HD group (p = 0.068).
A baseline anti-Vacc-C5 AB limit of 2000 ng/ml was
set according to subanalysis of a previous trial where
patients with higher pre-existing levels (> 2000 ng/ml
adjusted for assay differences) of anti-Vacc-C5 AB
experienced improved viral outcome following Vacc-4×
immunisation compared to placebo [24]. Patients with
baseline anti-Vacc-C5 AB levels >2000 ng/ml (n = 15)
showed a significant decrease in AB levels (p = 0.003),
whereas no change was observed in patients with levels
<2000 ng/ml (n = 13) (p = 0.859) (data not shown). Par-
ticipants with undetectable AB levels throughout the
study (n = 8) were excluded. Apart from the baseline AB
levels, the two groups were comparable.
Even if the overall changes in anti-Vacc-C5 AB levels
were small, individual differences were found. From
baseline to end of study, increased AB responses were
seen in six (17%) of the 36 vaccinated patients, a modest
increase of 5–65% (median 26%) compared to their
baseline levels. Four out of these six patients had detect-
able baseline levels. The six AB responders represented
all three dose groups (n = 3: 1: 2, LD: MD: HD, re-
spectively), and four had received intramuscular injec-
tions. Anti-Vacc-C5 AB responders (n = 6) and non-
responders (n = 30) were comparable in all baseline
characteristics except for the CD4+/CD8+ T cell ratio
(median 0.50 [IQR 0.38–0.59] and 0.69 [0.57–0.93], re-
spectively) (p = 0.046).
IFN-γ ELISPOT responses to Vacc-C5
At baseline, no significant differences in Vacc-C5 IFN-γ
responses were observed between any of the three dose
groups (Fig. 3b) or between the two modes of adminis-
tration (data not shown).
Only small changes in IFN-γ producing cells were seen
throughout the study, with a trend towards an overall
decrease in SFU (p = 0.090) (Fig. 3a). A significant
Table 1 Cohort characteristics
All (n = 36) Low dose (n = 12) Medium dose (n = 12) High dose (n = 12)
Age (years) 44.0 (38.5–49.7)a 45.2 (37.7–52.1) 46.3 (37.2–49.7) 42.7 (40.0–45.7)
Time since diagnosis (years) 5.2 (3.1–9.8) 4.9 (2.7–7.1) 5.0 (3.1–10.1) 8.7 (4.1–15.8)
Time on ART (years) 2.3 (1.4–3.9) 2.3 (1.6–2.7) 2.6 (1.7–4.1) 1.9 (1.3–6.6)
Nadir CD4 (cells/μl) 290 (234–360) 341 (265–396) 283 (234–343) 283 (227–358)
CD4 (cells/μl) 626 (529–758) 656 (572–756) 560 (526–679) 654 (557–831)
CD8 (cells/μl) 1051 (794–1250) 1109 (795–1223) 1032 (668–1282) 986 (805–1234)
HIV RNA (copies/ml) 0b(0 - <20) 0 (0 - <20) 0 (0 - <20) 0 (0 - <20)
No differences between the groups
aMedian (interquartile range)
b0 implies undetectable PCR product
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reduction was found in the HD group (p = 0.015) (Fig. 3b)
and the HD Alhydrogel subgroup (p = 0.028), whereas we
observed no changes within the LD or MD groups. Ana-
lysing all vaccinated, the Alhydrogel and GM-CSF groups
were comparable (data not shown).
Nevertheless, 13 (36%) of the study population showed
an increase in IFN-γ producing cells in response to Vacc-
C5 stimulation from baseline to end of study (n = 5: 6: 2,
LD: MD: HD, respectively). These responders were char-
acterised by a significantly lower CD8+ count at baseline
as compared to the non-responders (p = 0.005) and a
tendency of higher CD4+/CD8+ T cell ratio (p = 0.055)
(data not shown).
Vacc-C5-specific proliferative CD8+ and CD4+ T cell
responses
From baseline to end of study, Vacc-C5-specific prolifera-
tive T cell responses tended to increase in the CD8+ T cell
subset (p = 0.069). After the first booster period, CD8+ T
cell responses increased significantly (p = 0.020), but were
subsequently reduced after the second booster period
(Fig. 4a, upper panel).
In general, small changes in proliferative T cell re-
sponses were seen, although some patients developed
strong responses at different time points (Fig. 4b). At
end of study, improved responses in both T cell subsets
were found in nine patients (60%) including four (67%)
Table 2 Detailed cohort characteristics












Age (years) 44.0 (38.5–49.7) 45.2 (39.7–50.5) 44.4 (35.8–54.5) 37.2 (27.8–46.9) 49.7 (45.7–50.8) 44.0 (41.5–46.0) 40.1 (38.0–45.3)
Time since
diagnosis (years)
5.2 (3.1–9.8) 3.9 (2.2–6.3) 5.9 (3.0–7.29 4.1 (2.8–11.0) 6.4 (3.4–9.1) 5.9 (3.2–15.8) 9.8 (4.6–15.9)
Time on ART
(years)





318 (230–475) 357 (268–366) 283 (269–295)
(n = 5)
275 (234–343) 258 (228–380) 302 (219–340)
CD4 (cells/μl) 626 (529–758) 679 (580–1006) 656 (563–728) 610 (546–713) 529 (498–596) 654 (624–840) 706 (514–821)
CD8 (cells/μl) 1051 (794–1250) 1178 (798–2268) 1002 (764–1173) 921 (345–1256) 1104 (795–1308) 905 (658–1040) 1195 (932–1258)
HIV RNA
(copies/ml)





358 (211–845) 360 (268–840) 295 (210–398)
(n = 5)





7.3 × 104 (1.7 102





1.5 × 105 (2.6 104









1433 (390–4678) 390 (390–1934) 1341 (390–2396) 723 (390–4894) 1394 (458–5282) 1239 (390–4401) 7309 (3280–9772)
Median (interquartile range)
aMedian (min-max)
b0 implies undetectable PCR product
Fig. 2 Anti-Vacc-C5-specific antibodies (AB) in serum. a AB levels for the total cohort at week 1 (baseline), 6 (after initial immunisation),
15 (after1st boost) and 26 (after 2nd boost, end of study). Data are given as medians, interquartile and overall ranges. The change from
baseline to end of study is indicated (Wilcoxon matched pairs test). b AB levels for the three dose groups at week 1, 6, 15 and 26.
LD = low, MD = median and HD = high dose. Data are given as medians, interquartile and overall ranges. Changes within each dose
group with p-values less than 0.10 are indicated (Wilcoxon matched pairs test)
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of the six with enhanced ELISPOT responses at some
time point.
As a validation of the Tcell assays, we noted that the over-
all changes in Vacc-C5 specific responses by ELISPOT were
positively correlated with the overall changes in proliferative
responses from baseline to end of study (CD8+ r = 0.67,
p = 0.006; CD4+ r = 0.51, p = 0.050) (data not shown).
Vacc-C5-induced immune regulation
No Vacc-C5-induced cytokine-mediated T cell regulation
was detected at baseline (Fig. 5, left panel). In contrast,
there was a significant difference in Vacc-C5-specific
proliferative responses between cell cultures with and
without blockade of IL-10 and TGF-β after vaccination
(p = 0.006, both T cell subsets) (Fig. 5, right panel).
Fig. 3 Vacc-C5-specific IFN-γ responses. a IFN-γ responses for the total cohort at week 1 (baseline), 6 (after initial immunisation), 15 (after1st boost)
and 26 (after 2nd boost, end of study). Data are given as medians, interquartile and overall ranges. Changes with p-values less than 0.10 are
indicated (Wilcoxon matched pairs test). b IFN-γ responses for the three dose groups at week 1, 6, 15 and 26. LD = low, MD = median and
HD = high dose. Data are given as medians, interquartile and overall ranges. Significant changes within each dose group are indicated
(Wilcoxon matched pairs test)
Fig. 4 Vacc-C5-specific proliferative T cell responses. a Responses at week 1, 6, 15 and 26 in CD8+ (upper panel) and CD4+ (lower panel) T cell
subsets. Data are given as medians, interquartile and overall ranges. Changes with p-values 0.10 or less are indicated. b Individual responses
at week 1 (baseline), 6 (after initial immunisation), 15 (after1st boost) and 26 (after 2nd boost, end of study) in CD8+ (upper panel) and CD4+
(lower panel) T cell subsets
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Vacc-C5-induced cytokine-mediated net regulation in-
creased in both the CD8+ (p = 0.017) and CD4+
(p = 0.027) T cell subsets, mainly after the last booster
period (Fig. 6a). Overall, there was a three-fold increase
in regulation in the CD8+ T cell subset (p = 0.027)
(Fig. 6b). Notably, no correlations between prolifera-
tion and regulation were seen at end of study.
Five out of the six who increased in anti-Vacc-C5 AB
were among the 15 selected for T cell proliferation and
regulation assays. Interestingly, these five AB responders
had a significantly lower baseline regulation in the
CD8+ subset as compared to the ten non-responders
(p = 0.027) (data not shown).
T cell activation markers HLA-DR and CD38
Immune phenotyping was performed on unstimulated
PBMC from all patients. Some differences between groups
were found at baseline as the fraction of CD8+ T cells
expressing HLA-DR/CD38 was higher in the Alhydrogel
group (median 14.8% [IQR 11.8–18.3%]) than in the GM-
CSF group (11.5% [9.4–14.2%]) (p = 0.037). However, from
baseline to end of study, no changes in T cell activation
markers expressed as HLA-DR/CD38 were observed.
Soluble markers IP-10 and IL-6
To further investigate the possible influence of Vacc-C5
on immune activation, analyses of serum IP-10 and IL-6
were carried out, representing soluble markers that have
been associated with immune activation in HIV infec-
tion. In the total cohort, the levels of the pro-
inflammatory chemokine IP-10 were strongly associated
with the activation marker HLA-DR/CD38 on CD8+ T
cells at all four time points (r = 0.37–0.52, p = ≤ 0.025).
In contrast, no correlations were found for IL-6 (data
not shown). No differences between the dose groups or
modes of administration were seen for IP-10 and IL-6
Fig. 5 Vacc-C5-specific proliferative T cell responses without and with blockade of IL-10 and TGF-β in CD8+ (upper panel) and CD4+ (lower panel)
T cell subsets at week 1 (baseline) (left panel) and week 26 (end of study) (right panel). Significant differences are indicated (Wilcoxon matched
pairs test)
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levels at baseline. Within the different dose and adjuvant
groups there were no changes in the two parameters
throughout the study period (data not shown).
Discussion
In this phase I/II trial the therapeutic vaccine candidate
Vacc-C5 was administered over six months with initial
immunisation and two booster periods in the presence
of ART. The primary objective was to evaluate safety of
Vacc-C5 at three dose levels with two different adju-
vants, while the secondary objectives were to explore
humoral responses to Vacc-C5, HIV-associated immune
activation and T cell immunogenicity. Immune regula-
tion of T cell proliferative responses was an optional ex-
ploratory objective. Vacc-C5 was well tolerated, and all
36 patients completed the study. Despite rather low pre-
existing anti-Vacc-C5 AB levels at baseline, only mar-
ginal changes in humoral responses to Vacc-C5 were
found. Overall, both AB levels and T cell IFN-γ ELI-
SPOT responses decreased throughout the study. The
two modes of administration were comparable, with no
significant differences in Vacc-C5-induced responses be-
tween them. The higher doses appeared disadvantageous
as AB levels declined in the MD group, and a reduction
in IFN-γ responses was seen in the HD group.
Although intra- and inter-assay variations might cause
some of the minor changes in anti-Vacc-C5 AB levels,
the main conclusion is that marginal changes were in-
duced with the doses, schedule and adjuvants tested. It
should be noted that Vacc-C5 has been shown to induce
robust humoral responses in two classical animal
models; in sheep using Alhydrogel and in rabbits using
rh-GM-CSF as adjuvants (Bionor Pharma, data on file).
Although not tested in HIV seronegative volunteers for
regulatory and ethical reasons, Vacc-C5 was expected to
induce humoral responses in humans as well. Moreover,
if consistent enhancement of Vacc-C5 AB levels had
been observed, additional characterisation of Vacc-C5-
specific Ig isotype and subclass responses could have
been assessed, although no reference to such informa-
tion is available from reports on anti-C5 AB levels and
slow disease progression [5–7].
Despite the minimal changes in anti-Vacc-C5 AB
levels, some interesting data regarding T cell responses
were observed. It should be noted that the T cell re-
sponses to Vacc-C5 were generated by pooled peptides
representing the Env vaccine heterodimer, and did not
differentiate responses between the two short Env re-
gions. Overall, Vacc-C5 induced only small changes in
cellular responses from baseline to end of study. After
Fig. 6 Vacc-C5-induced T cell regulation. a Net regulation at week 1 (baseline), 6 (after initial immunisation), 15 (after1st boost) and 26 (after
2nd boost, end of study) in CD8+ (upper panel) and CD4+ (lower panel) T cell subsets. The change from baseline to end of study is indicated
(Wilcoxon matched pairs test). b Net regulation as fold increase at week 1 and 26. The change from baseline to end of study is indicated
(Wilcoxon matched pairs test)
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the first booster period, however, CD8+ T cell responses
significantly increased, but were subsequently reduced
after the second booster period. Strikingly, Vacc-C5-
induced cytokine-mediated immune regulation was the
only parameter that markedly increased during the trial.
We assessed a parameter for regulation by blocking the
two inhibitory cytokines IL-10 and TGF-β in Vacc-C5-
stimulated cell cultures. In previous studies, this param-
eter has been associated with rapid disease progression
[25] and inconsistent boosting effects of the HIV p24-
based Vacc-4× [22]. In a recent study, where Vacc-4×
was administered intranasally, immune regulation could
explain most cases of T cell anergy towards HIV p24 as
well as the variable final responses [23]. In the present
study, increased immune regulation might partially ex-
plain the coinciding declining T cell responses after the
second booster period (Figs. 4a and 6a) and possibly the
lack of anti-Vacc-C5 AB responses as well. Our data find
support in a recent primate prime and boost vaccination
model which has shown that a SIV vaccine can induce
suppressor cells and thereby dampen protective CD8+ T
cell responses [26].
Immune regulation may be quantified in different
ways. In previous papers [22, 23, 25], we have defined
antigen-induced cytokine-mediated regulation as a par-
ameter which also included control cultures with and
without mAbs to IL-10 and TGF-β. Net regulation is a
more simplified assessment, as reported by others [27]
and illustrated in Fig. 5. Net regulation might be easier
to comprehend, and is probably a more precise term to
use in the discussions of this phenomenon. A variant of
net regulation is fold increase, i.e. the ratio between pro-
liferative responses in stimulated cultures with and with-
out blockade. Here we explored immune regulation in
either way with generally identical results.
Our approach is supported in part by Brockman et al.
[27] who reported that blockade of the IL-10 pathway
increased proliferative T cell responses to HIV antigens
in viremic patients, whereas elite controllers and pa-
tients on effective ART failed to respond to the block-
ade. After immunisation with Vacc-C5, we found that
blocking of both IL-10 and TGF-β significantly in-
creased the proliferative capacity to Vacc-C5 in these
non-viremic patients. We have previously shown that
this parameter of T cell regulation is HIV antigen-
specific and not an inhibitory response to T cell activa-
tion in general. In an HIV positive individual, regula-
tion may be high to one specific HIV antigen but low
or absent to other HIV antigens and non-HIV antigens.
Moreover, regulation induced by different HIV antigens
are not correlated in a particular sample [25, 28].
Therefore, it is likely that the regulation induced by
Vacc-C5 is vaccine-specific and not a global T cell regu-
lation induced by the vaccine.
We chose to assess regulation by blocking two inhibi-
tory cytokines and quantify the total inhibitory effect on
Vacc-C5-specific T cell proliferation. Since proliferation
is a fundamental feature of effector T cells, the impact of
regulation on T cell proliferative capacity may provide
additional information, relevant for choosing patients
expected to benefit from therapeutic vaccination.
In the era of an HIV cure, there has been a renewed
interest in immunotherapy [29, 30]. Efficient HIV-specific
CD8+ cells able to eliminate reactivated latently infected
cells are essential to put HIV into remission [31], but these
cells are hampered in chronic HIV infection [32, 33].
Immunotherapy may therefore be required for an ef-
fective functional HIV cure, but a possible challenge
may be induction of immune regulation.
Both proliferative responses and immune regulation dif-
fered considerably from one patient to another through-
out the study. Consistent with previous results [22, 23],
our data highlight the importance of individualised im-
munotherapy. Moreover, they support the view that both
proliferative responses and regulation should be moni-
tored in therapeutic immunisation trials, because T cell
proliferation and immune regulation induced by a defined
HIV antigen are generally not correlated [25, 28].
This dose escalation study, with safety as primary ob-
jective, has limitations, particularly small size of each
adjuvant group. Regardless, it was possible to analyse
secondary endpoints in subgroups, but with the risk of
type II statistical errors. Moreover, the study was
planned and approved with no unimmunised or adju-
vant only control groups included. Another limitation
may be the selection of patients for proliferative assays.
Although proliferation and regulation were not tested
in all participants, these patients were comparable to
the rest of the cohort regarding clinical characteristics,
dose and administration as well as AB levels and IFN-γ
ELISPOT responses at baseline and end of study. The
regulatory assays could have been expanded to explore
the individual contribution by the two inhibitory cyto-
kines and to include other well characterised regulatory
pathways by blockade of T cell receptors like CTLA-4
and PD-1. Still, all the above mentioned regulatory
pathways are recently addressed by our group, and the
combined blockade of IL-10 and TGF-β was found to
best identify net regulation induced by Env antigens
[28]. Finally, more direct methods to assess regulation
might have provided even more definitive data, e.g. separ-
ation of T regulatory cells by cell sorting and add-back ex-
periments with the sorted cells. However, these in-depth
analyses would require substantial PBMC and resources
unrealistic to implement in a clinical trial setting.
The development of Vacc-C5 was based on the hy-
pothesis that the C5 region is involved in chronic im-
mune activation and that blocking this domain with
Brekke et al. BMC Infectious Diseases  (2017) 17:228 Page 10 of 12
non-neutralising AB may lead to reduced immune acti-
vation and disease progression [10, 11]. However, in
this study including patients on ART, increased levels
of anti-Vacc-C5 AB were not induced, and the activa-
tion markers HLA-DR/CD38 and the two chosen
pro-inflammatory mediators IP-10 and IL-6 remained
unchanged. Since the C5 domain shows sequence simi-
larity to HLA-DR, the HLA phenotype of study partici-
pants may potentially have influenced the results.
Finally, it might be possible that Vacc-C5 administered
with another adjuvant or with a carrier molecule could
have generated AB with effects on HIV-associated im-
mune activation.
Conclusions
In this study investigating safety and immunogenicity of
the therapeutic vaccine candidate Vacc-C5, only mar-
ginal immune responses were safely induced, whereas
vaccine-specific regulation clearly increased after com-
pleted vaccination. It is said that we learn more from
failure than success (Samuel Smiles 1812–1904, Scottish
author and reformer). Despite the absence of enhanced
immune responses, this study might still provide insights
to improve future therapeutic vaccine designs and im-
munotherapy and encourage further focus on immune
regulation in therapeutic vaccination.
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